Takeda Gives Mellinnium Task To Select Best Cancer Drug Candidates
This article was originally published in PharmAsia News
Takeda Pharmaceutical is turning over the decision-making about its pipeline of oncology drugs to its American biotech subsidiary, Millennium Pharmaceuticals. Takeda has 15 drugs for treating cancer in clinical trials, but has decided to let Mellinnium draw on its expertise and technology to select the best candidates from among them and speed their development. Takeda is more familiar with hypertension and diabetes drugs, but several best-sellers in those groups face patent expirations next year. (Click here for more - a subscription may be required
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.